Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease

Gamma-glutamyl transferase predicts pemafibrate treatment response in non-alcoholic fatty liver disease

Pemafibrate, a selective peroxisome proliferator activated receptor α modulator, has been shown to improve liver function among nonalcoholic fatty liver disease (NAFLD) patients with dyslipidemia. The aim of this retrospective study is to identify predictors of pemafibrate efficacy in NAFLD patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of gastroenterology and hepatology 2023-10, Vol.38 (10), p.1743-1749
Hauptverfasser: Takahashi, Yusuke, Seko, Yuya, Yamaguchi, Kanji, Takeuchi, Kento, Yano, Kota, Kataoka, Seita, Moriguchi, Michihisa, Itoh, Yoshito
Format: Artikel
Sprache:eng
Schlagworte:
Alanine transaminase
Aspartate aminotransferase
Dyslipidemia
Fatty liver
Liver diseases
Metabolic disorders
Triglycerides
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pemafibrate, a selective peroxisome proliferator activated receptor α modulator, has been shown to improve liver function among nonalcoholic fatty liver disease (NAFLD) patients with dyslipidemia. The aim of this retrospective study is to identify predictors of pemafibrate efficacy in NAFLD patients. A total of 75 NAFLD patients with dyslipidemia who received pemafibrate twice per day for 48 weeks were enrolled in this study. We used the FibroScan-aspartate aminotransferase (FAST) score as a benchmark for treatment efficacy. Median FAST score significantly decreased from 0.96 at baseline to 0.93 at week 48 (P 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.16222